



## **Vericel to Present at the 17th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019**

September 4, 2019 at 8:00 AM EDT

CAMBRIDGE, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 17<sup>th</sup> Annual Morgan Stanley Global Healthcare Conference in New York on Wednesday, September 11, 2019 at 12:15pm Eastern Time.

A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: <http://investors.vcel.com>

### **About Vericel Corporation**

Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI<sup>®</sup> (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel<sup>®</sup> (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid<sup>®</sup>, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company's website at [www.vcel.com](http://www.vcel.com).

Epicel<sup>®</sup> and MACI<sup>®</sup> are registered trademarks of Vericel Corporation. NexoBrid<sup>®</sup> is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2019 Vericel Corporation. All rights reserved.

### **Global Media Contacts:**

David Schull  
Russo Partners LLC  
[David.schull@russopartnersllc.com](mailto:David.schull@russopartnersllc.com)  
+1 212-845-4271 (office)  
+1 858-717-2310 (mobile)

Karen Chase  
Russo Partners LLC  
[Karen.chase@russopartnersllc.com](mailto:Karen.chase@russopartnersllc.com)  
+1 646-942-5627 (office)  
+1 917-547-0434 (mobile)

### **Investor Contacts:**

Chad Rubin  
Solebury Trout  
[crubin@troutgroup.com](mailto:crubin@troutgroup.com)  
+1 646-378-2947

Lee Stern  
Solebury Trout  
[lsfern@troutgroup.com](mailto:lsfern@troutgroup.com)  
+1 646-378-2922